Literature DB >> 34988943

Establishment of Human Induced Pluripotent Stem Cells from Multiple Sclerosis Patients.

Onur Can Begentas1, Dilara Koc1, Erkan Kiris2.   

Abstract

The patient-derived iPSC lines provide valuable resources as these cells can be utilized to generate human cell types relevant to the disease of interest. In this context, human iPSC-based model systems are particularly useful for neurological diseases as the neuron and glial cell types affected by such diseases are difficult to obtain. Multiple sclerosis is a demyelinating central nervous system disease characterized by inflammation and eventually axonal damage. iPS cells generated from MS patients may allow for unique approaches for studying the disease in a species-specific manner, with a potentially limitless supply of patients' own glial and neuronal cells differentiated from the iPSCs. Here we describe the detailed protocol for establishing iPSCs from peripheral blood mononuclear cells that we have utilized to model multiple sclerosis. We particularly focused on optimized and cost-effective procedures using the integration-free Sendai virus-based reprogramming method for the generation and characterization of MS iPSCs.
© 2021. Springer Science+Business Media, LLC.

Entities:  

Keywords:  Disease modeling; Human induced pluripotent stem cells; Multiple sclerosis; Pluripotency; Sendai virus-based reprogramming

Mesh:

Year:  2022        PMID: 34988943     DOI: 10.1007/7651_2021_453

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  17 in total

Review 1.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

Review 2.  Multiple sclerosis.

Authors:  Alan J Thompson; Sergio E Baranzini; Jeroen Geurts; Bernhard Hemmer; Olga Ciccarelli
Journal:  Lancet       Date:  2018-03-23       Impact factor: 79.321

Review 3.  Biological models in multiple sclerosis.

Authors:  Alfredo Sanabria-Castro; Marietta Flores-Díaz; Alberto Alape-Girón
Journal:  J Neurosci Res       Date:  2019-10-01       Impact factor: 4.164

Review 4.  Treatment of Multiple Sclerosis: A Review.

Authors:  Stephen L Hauser; Bruce A C Cree
Journal:  Am J Med       Date:  2020-07-17       Impact factor: 4.965

5.  Generation of six multiple sclerosis patient-derived induced pluripotent stem cell lines.

Authors:  L Miquel-Serra; A Duarri; Y Muñoz; B Kuebler; B Aran; C Costa; M Martí; M Comabella; S Malhotra; X Montalban; A Veiga; A Raya
Journal:  Stem Cell Res       Date:  2017-06-07       Impact factor: 2.020

Review 6.  Multiple Sclerosis.

Authors:  Daniel S Reich; Claudia F Lucchinetti; Peter A Calabresi
Journal:  N Engl J Med       Date:  2018-01-11       Impact factor: 91.245

Review 7.  Promoting remyelination in multiple sclerosis.

Authors:  Nick Cunniffe; Alasdair Coles
Journal:  J Neurol       Date:  2019-06-12       Impact factor: 4.849

Review 8.  Revisiting remyelination: Towards a consensus on the regeneration of CNS myelin.

Authors:  Robin J M Franklin; Jonas Frisén; David A Lyons
Journal:  Semin Cell Dev Biol       Date:  2020-10-18       Impact factor: 7.727

9.  Animal models of multiple sclerosis: the good, the bad and the bottom line.

Authors:  Richard M Ransohoff
Journal:  Nat Neurosci       Date:  2012-07-26       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.